Chauhan A, et al. - Researchers assessed clinical activity of the combination of capecitabine and temozolomide (CAPTEM) in neuroendocrine tumors (NET) of unknown primary via a retrospective review of NET of unknown primary managed at the University of Kentucky over the past five years (2012–2016). In grade II and grade III NET of unknown primary treated with CAPTEM, the median progression-free survival was noted to be 10.8 and 7 months, respectively. Common side-effects included grade II thrombocytopenia, grade I lymphocytopenia, hand foot syndrome (grades I and III), and grade I fatigue. Overall, considering CAPTEM for grades I and II NET of unknown primary was recommended, especially in the case of visceral crisis or bulky disease.